Serial Success With Triumvira's Rob Williamson

Business Of Biotech

Inhoud geleverd door Matt Pillar. Alle podcastinhoud, inclusief afleveringen, afbeeldingen en podcastbeschrijvingen, wordt rechtstreeks geüpload en geleverd door Matt Pillar of hun podcastplatformpartner. Als u denkt dat iemand uw auteursrechtelijk beschermde werk zonder uw toestemming gebruikt, kunt u het hier beschreven proces https://nl.player.fm/legal volgen.

6M ago 31:32

MP3•Thuis aflevering

We love to hear from our listeners. Send us a message.

Rob Williamson's mind and hands have shaped more than 20 biotech startups, leading some to IPO and landing others firmly in Big Bio through acquisition by companies like Merck. Hanging around as many successful exits as Williamson has seen, one might become expert via osmosis. But Williamson isn't passive about honing his vision for progressive therapeutic dealmaking. He's an active leader, and for this episode of the Business of Biotech, he took a breather from a hectic agenda at the J.P. Morgan Healthcare Conference to share some introspection on the work he's done, the work he's doing at Triumvira with T-cell therapeutics in oncology, the big opportunities in cancer therapeutics, and what's coming next.
Access this and hundreds of episodes of the Business of Biotech videocast under the Listen & Watch tab at bioprocessonline.com.

Subscribe to our monthly Business of Biotech newsletter.
Get in touch with guest and topic suggestions: matt.pillar@lifescienceconnect.com
Find Matt Pillar on LinkedIn: https://www.linkedin.com/in/matthewpillar/

Hoofdstukken

1. Biotech Entrepreneurship and Cancer Therapy (00:00:00)

2. Exploring Oncology and Therapeutic Innovations (00:13:33)

3. Navigating Biotech Partnerships and Investments (00:21:21)

4. Planning Future Biotech Podcast Episodes (00:30:22)

218 afleveringen

#Science #MBA #Biology #Business #Matt Pillar #Biopharmaceutical #Bioprocess #Biopharma #Medicine #Therapy #Startup #Venturecapital #Entrepreneur #Pharma #Biotech